LOXL2 and breast cancer: Inhibition of the collagen-crosslinking lysyl oxidase (LOX) family in mice decreased fibrosis as well as tumor incidence and tumor size in a mouse model [6], and high lysyl oxidase-like 2 (LOXL2) expression correlates with low overall and metastasis-free survival in breast cancer patients [7].